Matrix metalloproteinases in blood from patients with LAM

Nao Odajima, Tomoko Betsuyaku, Yasuyuki Nasuhara, Hiromasa Inoue, Kuniaki Seyama, Masaharu Nishimura

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) is characterized by the proliferation of abnormal smooth muscle cells (LAM cells) and destruction of alveolar structure. Immunohistochemical studies suggest that excess matrix metalloproteinases (MMPs) synthesized by LAM cells function in the proteolytic mechanisms of this disease. We postulated MMP levels in the blood are elevated in LAM patients. Serum samples were collected from 36 LAM patients and 25 controls, and gelatinolytic activities were semi-quantified by gelatin zymography. The reliability of serum data for MMP-9 was confirmed by the measurement of MMP-9 concentration in plasma by enzyme-linked immunosorbent assay as well as by gelatin zymography. Serum levels of MMP-9 (0.7 ± 0.1 AU), but not MMP-2, were significantly elevated in LAM patients compared with controls (0.1 ± 0 AU). Plasma and serum levels of MMP-9 significantly correlated. These results suggest the involvement of MMP-9 in LAM.

Original languageEnglish
Pages (from-to)124-129
Number of pages6
JournalRespiratory Medicine
Volume103
Issue number1
DOIs
Publication statusPublished - 2009 Jan 1

Keywords

  • Lymphangioleiomyomatosis
  • MMP-2
  • MMP-9
  • Plasma
  • Serum

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Matrix metalloproteinases in blood from patients with LAM'. Together they form a unique fingerprint.

  • Cite this

    Odajima, N., Betsuyaku, T., Nasuhara, Y., Inoue, H., Seyama, K., & Nishimura, M. (2009). Matrix metalloproteinases in blood from patients with LAM. Respiratory Medicine, 103(1), 124-129. https://doi.org/10.1016/j.rmed.2008.07.017